Human Immunodeficiency Virus Associated Plasmablastic Lymphoma Involving Bones and Peritoneum in a 4-Year-old Child

Subramaniam Ramanathan1, Nirmalya Roy Moulik2, Chetan Dhamne2

  • 1Department of Paediatric Oncology, Great North Children's Hospital, Newcastle-upon-Tyne, UK.

Insights

Pediatric non-Hodgkin lymphoma, specifically plasmablastic lymphoma, is rare but can occur in children with Human Immunodeficiency virus (HIV) infection and Acquired Immunodeficiency Syndrome (AIDS). Early treatment with chemotherapy and antiretroviral therapy led to remission in a young boy with knee joint plasmablastic lymphoma.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Infectious Diseases

Background:

  • Hematolymphoid cancers, particularly non-Hodgkin lymphomas, are prevalent in children with Human Immunodeficiency virus (HIV) infection and Acquired Immunodeficiency Syndrome (AIDS).
  • Plasmablastic lymphoma (PBL) is an aggressive non-Hodgkin lymphoma subtype, typically affecting the head and neck region, and is exceptionally rare in pediatric populations.
  • The occurrence of PBL in extranodal sites, such as the knee joint in HIV-infected children, presents a diagnostic and therapeutic challenge.

Observation:

  • A 4-year-old boy with an underlying Human Immunodeficiency virus infection presented with a solitary bony swelling localized to the right knee joint.
  • Diagnostic investigations confirmed the swelling to be a case of plasmablastic lymphoma, an unusual presentation for this specific malignancy in a pediatric patient.
  • The patient's clinical course was meticulously monitored following diagnosis.

Findings:

  • The diagnosis of plasmablastic lymphoma was established through comprehensive work-up of the knee joint swelling.
  • The child received a treatment regimen comprising combination chemotherapy and intrathecal chemotherapy.
  • Highly active anti-retroviral therapy (HAART) was initiated early in conjunction with cancer-directed treatment.

Implications:

  • This case highlights the importance of considering rare presentations of plasmablastic lymphoma in immunocompromised children.
  • The successful outcome underscores the efficacy of a multimodal treatment approach, including chemotherapy and early HAART, in managing pediatric plasmablastic lymphoma.
  • Further research into the specific oncogenesis and optimal management strategies for extranodal plasmablastic lymphoma in HIV-infected children is warranted.